Comparison of treatment-emergent resistance-associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor-based single-tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV: A systematic literature review and network meta-analysis
Abstract
Objective
This study evaluated rates of treatment‐emergent resistance‐associated mutations (TE‐RAMs) and discontinuation due to adverse events (DC‐AEs) across integrase strand transfer inhibitor (INSTI)‐based single‐tablet regimens and injectable cabotegravir + rilpivirine (CAB + RPV) in virologically suppressed people with HIV.
Methods
A systematic literature review was conducted for phase 2–4 randomized controlled trials with ≥48 weeks of follow‐up involving virologically suppressed people with HIV aged ≥12 years and published January 2003–March 2024. A random‐effects network meta‐analysis estimated comparative rates of TE‐RAMs and DC‐AEs among regimens at 48 weeks. Risk of bias and strength of evidence were assessed using Cochrane RoB and CINeMA, respectively.
Results
Fourteen (7509 participants) and nine (4656 participants) studies were included in the TE‐RAMs and DC‐AEs analyses, respectively. No significant differences in rates of TE‐RAMs were observed; risk ratios (RRs) for TE‐RAMs for bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) and CAB + RPV every 4 weeks (Q4W) versus CAB + RPV every 8 weeks (Q8W) were 0.22 (95% CI, 0.02–2.04), 0.22 (95% CI, 0.00–19.85) and 0.40 (95% CI, 0.14–1.09). Compared with CAB + RPV Q4W and Q8W, DC‐AEs were significantly lower with B/F/TAF (RR, 0.15 [95% CI, 0.03–0.75] and RR, 0.16 [95% CI, 0.04–0.67], respectively) and DTG/ABC/3TC (RR, 0.05 [95% CI, 0.01–0.48] and RR, 0.05 [95% CI, 0.01–0.46], respectively).
Conclusions
In virologically suppressed people with HIV, switching to CAB + RPV Q8W yielded a non‐significant increased risk of TE‐RAMs compared with INSTI‐based 2‐ and 3‐drug regimens and CAB + RPV Q4W. Both CAB + RPV Q4W and Q8W had significantly higher risks of DC‐AEs than B/F/TAF and DTG/ABC/3TC. Findings highlight the importance of considering both resistance and tolerability when switching regimens.
Authors
Rashid I, Unger NR, Willis C, Dhippayom T, Ramgopal M, Sherman EM, Yared N, Safran R, Swiatlo E, Weinberg AR, Navadeh S, Schmutz HW, Chaiyakunapruk N
Year
2025
Topics
- Population(s)
- General HIV+ population
- Other
- Prevention, Engagement and Care Cascade
- Engagement and Care Cascade
- Engagement and Care Cascade
- Treatment
